Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$11.35
-1.00-8.10%
At close: -
$11.35
0.000.00%
After Hours: Jun 27, 7:44 PM EDT
Comments
Loading...
Benitec Biopharma Analyst Ratings and Price Targets | NASDAQ:BNTC | Benzinga
Benitec Biopharma Inc has a consensus price target of $21.67 based on the ratings of 9 analysts. The high is $35 issued by Oppenheimer on October 16, 2024. The low is $4 issued by HC Wainwright & Co. on September 23, 2022. The 3 most-recent analyst ratings were released by HC Wainwright & Co., JMP Securities, and JMP Securities on May 19, 2025, May 15, 2025, and April 10, 2025, respectively. With an average price target of $22.67 between HC Wainwright & Co., JMP Securities, and JMP Securities, there's an implied 99.71% upside for Benitec Biopharma Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
JMP Securities
Citizens Capital Markets
Baird
Guggenheim
1calculated from analyst ratings
Analyst Ratings for Benitec Biopharma
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/19/2025 | Buy Now | 146.7% | HC Wainwright & Co. | Raghuram Selvaraju44% | $28 → $28 | Reiterates | Buy → Buy | Get Alert |
| 05/15/2025 | Buy Now | 76.21% | JMP Securities | Silvan Tuerkcan49% | $20 → $20 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 04/10/2025 | Buy Now | 76.21% | JMP Securities | Silvan Tuerkcan49% | $18 → $20 | Maintains | Market Outperform | Get Alert |
| 03/24/2025 | Buy Now | 146.7% | HC Wainwright & Co. | Raghuram Selvaraju44% | $28 → $28 | Reiterates | Buy → Buy | Get Alert |
| 03/18/2025 | Buy Now | 58.59% | Citizens Capital Markets | Silvan Tuerkcan49% | $18 → $18 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 02/21/2025 | Buy Now | 146.7% | HC Wainwright & Co. | Raghuram Selvaraju44% | $28 → $28 | Reiterates | Buy → Buy | Get Alert |
| 12/13/2024 | Buy Now | 164.32% | Baird | Brian Skorney58% | → $30 | Initiates | → Outperform | Get Alert |
| 12/03/2024 | Buy Now | 49.78% | Guggenheim | Debjit Chattopadhyay55% | $17 → $17 | Reiterates | Buy → Buy | Get Alert |
| 10/16/2024 | Buy Now | 208.37% | Oppenheimer | Andreas Argyrides70% | → $35 | Initiates | → Outperform | Get Alert |
| 10/14/2024 | Buy Now | 58.59% | JMP Securities | Silvan Tuerkcan49% | $16 → $18 | Maintains | Market Outperform | Get Alert |
| 09/30/2024 | Buy Now | 40.97% | JMP Securities | Silvan Tuerkcan49% | $16 → $16 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 09/12/2024 | Buy Now | 49.78% | Guggenheim | Debjit Chattopadhyay55% | → $17 | Initiates | → Buy | Get Alert |
| 07/22/2024 | Buy Now | 14.54% | Leerink Partners | Mani Foroohar50% | → $13 | Initiates | → Outperform | Get Alert |
| 06/13/2024 | Buy Now | 164.32% | Piper Sandler | Yasmeen Rahimi62% | → $30 | Initiates | → Overweight | Get Alert |
| 04/22/2024 | Buy Now | 40.97% | JMP Securities | Silvan Tuerkcan49% | $10 → $16 | Maintains | Market Outperform | Get Alert |
| 02/15/2024 | Buy Now | -11.89% | JMP Securities | Silvan Tuerkcan49% | $8 → $10 | Maintains | Market Outperform | Get Alert |
| 01/24/2024 | Buy Now | -29.52% | JMP Securities | Silvan Tuerkcan49% | $6 → $8 | Maintains | Market Outperform | Get Alert |
| 09/26/2023 | Buy Now | -47.14% | JMP Securities | Silvan Tuerkcan49% | $4 → $6 | Maintains | Market Outperform | Get Alert |
| 06/26/2023 | Buy Now | -64.76% | JMP Securities | Silvan Tuerkcan49% | → $4 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 05/18/2023 | Buy Now | -64.76% | JMP Securities | Silvan Tuerkcan49% | $4 → $4 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 10/18/2022 | Buy Now | -64.76% | JMP Securities | Silvan Tuerkcan49% | → $4 | Initiates | → Market Outperform | Get Alert |
| 09/23/2022 | Buy Now | -64.76% | HC Wainwright & Co. | Patrick Trucchio49% | $10 → $4 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Benitec Biopharma (BNTC) stock?
The latest price target for Benitec Biopharma (NASDAQ:BNTC) was reported by HC Wainwright & Co. on May 19, 2025. The analyst firm set a price target for $28.00 expecting BNTC to rise to within 12 months (a possible 146.70% upside). 13 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Benitec Biopharma (BNTC)?
The latest analyst rating for Benitec Biopharma (NASDAQ:BNTC) was provided by HC Wainwright & Co., and Benitec Biopharma reiterated their buy rating.
When was the last upgrade for Benitec Biopharma (BNTC)?
There is no last upgrade for Benitec Biopharma
When was the last downgrade for Benitec Biopharma (BNTC)?
There is no last downgrade for Benitec Biopharma.
When is the next analyst rating going to be posted or updated for Benitec Biopharma (BNTC)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Benitec Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Benitec Biopharma was filed on May 19, 2025 so you should expect the next rating to be made available sometime around May 19, 2026.
Is the Analyst Rating Benitec Biopharma (BNTC) correct?
While ratings are subjective and will change, the latest Benitec Biopharma (BNTC) rating was a reiterated with a price target of $28.00 to $28.00. The current price Benitec Biopharma (BNTC) is trading at is $11.35, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
